"Dry Powder Inhalers" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A device that delivers medication to the lungs in the form of a dry powder.
| Descriptor ID |
D058995
|
| MeSH Number(s) |
E07.605.500
|
| Concept/Terms |
Dry Powder Inhalers- Dry Powder Inhalers
- Dry Powder Inhaler
- Inhaler, Dry Powder
- Inhalers, Dry Powder
- Powder Inhaler, Dry
- Powder Inhalers, Dry
|
Below are MeSH descriptors whose meaning is more general than "Dry Powder Inhalers".
Below are MeSH descriptors whose meaning is more specific than "Dry Powder Inhalers".
This graph shows the total number of publications written about "Dry Powder Inhalers" by people in this website by year, and whether "Dry Powder Inhalers" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dry Powder Inhalers" by people in Profiles.
-
Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate? AAPS J. 2021 03 25; 23(3):48.
-
Maintenance inhaler therapy preferences of patients with asthma or chronic obstructive pulmonary disease: a discrete choice experiment. Thorax. 2020 09; 75(9):735-743.
-
A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD. Respir Med. 2016 11; 120:16-24.
-
Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients. Respir Med. 2014 Aug; 108(8):1171-9.
-
Perceptions and attitudes toward the use of nebulized therapy for COPD: patient and caregiver perspectives. COPD. 2013 Aug; 10(4):482-92.
-
Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros. 2011 Jan; 10(1):54-61.